Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2022; 10(27): 9743-9749
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9743
Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
Shu-Guang Zhu, Hai-Bo Li, Tian-Xing Dai, Hua Li, Guo-Ying Wang
Shu-Guang Zhu, Hai-Bo Li, Tian-Xing Dai, Hua Li, Guo-Ying Wang, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China
Guo-Ying Wang, Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, Guangdong Province, China
Author contributions: Zhu SG and Li HB contributed equally to this work; Wang GY and Li HB designed the research study; Zhu SG, Li HB, and Dai TX performed the research and wrote the manuscript; all authors have read and approved the final manuscript.
Supported by The National 13th Five-Year Science and Technology Plan Major Projects of China, No. 2017ZX10203205-006-001 and No. 2017ZX10203205-001-003.
Informed consent statement: The patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guo-Ying Wang, MD, PhD, Associate Professor, Chief Doctor, Director, Surgeon, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Tianhe District, Guangzhou 510630, Guangdong Province, China. wanggy3@126.com
Received: November 9, 2021
Peer-review started: November 9, 2021
First decision: December 27, 2021
Revised: January 24, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 26, 2022
Processing time: 310 Days and 19.5 Hours
Core Tip

Core Tip: At present, the objective remission rate of intrahepatic cholangiocarcinoma (ICC) in the treatment of advanced hepatocellular carcinoma (HCC) patients is approximately 20%. The development of more sensitive and efficient predictive methods will improve the benefits of ICC therapy in potential patients with advanced HCC and benefit patients who are suitable for ICC therapy. This will hopefully open up a new prospect of immunotherapy for liver tumors. Immunotherapy may be a potential treatment option for ICC.